Innate Pharma has moved 17.1% so far today on a volume of 395,210, compared to its average of 71,509. In contrast, the S&P 500 index moved -0.1%. Over the last 52 weeks, the stock moved -41.7%, with a high of $5.25 and a low of $1.9. During this time, the stock lagged the S&P 500 index by -22.0%.
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The small-cap Healthcare company has 213 full time employees and is based in Marseille, France. Innate Pharma has not offered any dividends in the last year.
Snapshot of the Company's Lack of Profitability:
|Gross Margins Growth||n/a||inf%||174.11%||-100.0%|
|Operating Margins Growth||n/a||-709.01%||16.8%||-1110.36%|
|Free Cash Flow (MM)||$-34||$-30||$-63||$-60|
|Capital Expenditures (MM)||$-1||$-65||$-11||$-1|
|Net Debt / EBITDA||-12.05||21.01||-3.1||1.43|
Basic Valuation Metrics Show Innate pharma Is Overvalued:
Compared to the Healthcare sector's average of 13.21, Innate Pharma has a trailing twelve month price to earnings (P/E) ratio of -4.7 and, based on its Eps guidance of 0.45, an expected P/E ratio of 7.3. Innate Pharma's price to book (P/B) ratio is 2.3 compared to its sector average of 4.07.
There is Mixed Market Sentiment About Innate Pharma:
5 analysts are following Innate Pharma and have set target prices ranging from $2.51 to $12.02 per share. On average, they have given the company a rating of buy. At today's prices, IPHA is trading -58.98% away from its average analyst target price of $8.02 per share, implying an analyst consensus of strong upside potential for the stock.